» Articles » PMID: 22354785

Role of PRAS40 in Akt and MTOR Signaling in Health and Disease

Overview
Date 2012 Feb 23
PMID 22354785
Citations 90
Authors
Affiliations
Soon will be listed here.
Abstract

The proline-rich Akt substrate of 40 kDa (PRAS40) acts at the intersection of the Akt- and mammalian target of rapamycin (mTOR)-mediated signaling pathways. The protein kinase mTOR is the catalytic subunit of two distinct signaling complexes, mTOR complex 1 (mTORC1) and mTORC2, that link energy and nutrients to the regulation of cellular growth and energy metabolism. Activation of mTOR in response to nutrients and growth factors results in the phosphorylation of numerous substrates, including the phosphorylations of S6 kinase by mTORC1 and Akt by mTORC2. Alterations in Akt and mTOR activity have been linked to the progression of multiple diseases such as cancer and type 2 diabetes. Although PRAS40 was first reported as substrate for Akt, investigations toward mTOR-binding partners subsequently identified PRAS40 as both component and substrate of mTORC1. Phosphorylation of PRAS40 by Akt and by mTORC1 itself results in dissociation of PRAS40 from mTORC1 and may relieve an inhibitory constraint on mTORC1 activity. Adding to the complexity is that gene silencing studies indicate that PRAS40 is also necessary for the activity of the mTORC1 complex. This review summarizes the regulation and potential function(s) of PRAS40 in the complex Akt- and mTOR-signaling network in health and disease.

Citing Articles

Activin A affects colorectal cancer progression and immunomodulation in a stage dependent manner.

Wiley M, Bauer J, Alvarez V, Kolics Z, Cheng W, Church D Sci Rep. 2025; 15(1):8509.

PMID: 40075112 PMC: 11903883. DOI: 10.1038/s41598-025-91853-9.


Metabolic Reprograming of Macrophages: A New Direction in Traditional Chinese Medicine for Treating Liver Failure.

Zhang J, Li N, Hu X J Immunol Res. 2025; 2024():5891381.

PMID: 39741958 PMC: 11688140. DOI: 10.1155/jimr/5891381.


Unveiling the Role of Mechanistic Target of Rapamycin Kinase (MTOR) Signaling in Cancer Progression and the Emergence of MTOR Inhibitors as Therapeutic Strategies.

Mehta D, Rajput K, Jain D, Bajaj A, Dasgupta U ACS Pharmacol Transl Sci. 2024; 7(12):3758-3779.

PMID: 39698262 PMC: 11650738. DOI: 10.1021/acsptsci.4c00530.


Targeting the mTOR-Autophagy Axis: Unveiling Therapeutic Potentials in Osteoporosis.

Chen R, Yang C, Yang F, Yang A, Xiao H, Peng B Biomolecules. 2024; 14(11).

PMID: 39595628 PMC: 11591800. DOI: 10.3390/biom14111452.


Phospholipase Cδ-4 (PLCδ4) Acts as a Nuclear Player to Influence Cyclin B Expression in the Embryonal Rhabdomyosarcoma Cell Lines RD and A204.

Salucci S, Bavelloni A, Versari I, Burattini S, Bavelloni F, Gobbi P Biomolecules. 2024; 14(9).

PMID: 39334946 PMC: 11430102. DOI: 10.3390/biom14091180.